New Low-Dose drug schedule shows promise for MDS patients
Disease control
Completed
This study tested different low doses and schedules of the drug ASTX727 in 160 adults with lower-risk myelodysplastic syndromes (MDS), a type of blood cancer. The goal was to find a dose that improves blood cell counts and reduces the need for blood transfusions while being safe.…
Phase: PHASE1, PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC